Nxera Pharma

5 November 2024 –Tokyo, Japan and London and Cardiff, UK – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). The collaboration…

27 June 2024, Tokyo, Japan and Cambridge, UK – Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in a payment of US$10m to Nxera. Nxera and AbbVie entered into this multi-target collaboration in 2022 to leverage…

9 May 2024 — Tokyo, Japan and Cambridge, UK — Nxera Pharma provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2024. The full report can be found here: investors.nxera.life/library/results. Chris Cargill, president and CEO of Nxera, commented: “We entered 2024 with a clear vision to…